Leadership & Pay ·
Akari CEO's base salary raised to $625,000 with new RSUs and options
AKTXAkari Therapeutics Plc
Akari Therapeutics amended its CEO Abizer Gaslightwala’s agreement, raising his annual base salary from $475,000 to $625,000 effective August 18, 2026. Ten percent of the increase will be paid in restricted stock units vesting quarterly through August 2027, subject to shareholder approval for plan amendments. The target bonus opportunity also increased from 50% to 55% of base salary, bringing total target compensation to approximately $970,000. Additionally, the CEO received options to purchase 174,000 ADSs vesting monthly over four years. Akari Therapeutics is a clinical-stage biopharmaceutical company developing therapies for rare diseases.